Topbet216 - Sports betting, Casino, Online Games Topbet216 Company is one of the leading betting sites. Wide range of sports live streams of football, basketball, volleyball, tennis, ice hockey, horse racing etc. About 28,000 live matches yearly, poker events, casino. Pfizer Stock: A Top Bet for 2021? This is an enormous achievement expected to generate more than $10 billion in top-line sales for the collaboration partners this year, and then sharply taper. Krieger's average cost works out to $55.77/share. Shares of Ormat Technologies Inc were changing hands at $118.64 at last check, trading off about 4.8% on Friday. The chart below shows the one.
© Provided by The Motley Fool Pfizer Stock: A Top Bet for 2021?Top Bethesda Restaurants
If you've spent any amount of time hunting for stocks to buy in 2021, Pfizer(NYSE: PFE) and its recently authorized coronavirus vaccine probably caught your attention.
Top Bet Uk
Pfizer and its partner BioNTech(NASDAQ: BNTX) rapidly developed a new vaccine to prevent COVID-19. This is an enormous achievement expected to generate more than $10 billion in top-line sales for the collaboration partners this year, and then sharply taper off in 2022. That's nothing to sneeze at, but it's important to realize Pfizer already expects more than $40 billion in total revenue this year.
Over the past 12 months, Pfizer's profitable operation generated a whopping $10.3 billion in free cash flow, and 2021 was already shaping up to be a great year before the Food and Drug Administration (FDA) authorized its COVID-19 vaccine. Sales of Vyndaqel, a rare-disease treatment Pfizer launched in the U.S. in 2019, more than doubled year over year to reach an annualized $1.4 billion during the third quarter.
Late last year, Pfizer spun off UpJohn, its post-market-exclusivity segment, which merged with Mylan to form Viatris. The sale to Mylan netted Pfizer $12 billion in net proceeds that can be used to make dividend payments and invest in tomorrow's potential new sources of revenue.
Pfizer has raised its dividend every year since 2009, and investors who have held their shares over the past decade have seen their payouts double in size. At recent prices, the stock offers a 4.2% yield that you get to keep no matter what happens to Pfizer or the economy at large.
Video: Jim Cramer Says Georgia Race Isn't Reason to Buy Cannabis Stocks (TheStreet)
Pfizer is an established pharma giant, but its shares aren't going to double overnight. Still, it's a top bet for investors who can't or won't take big risks with their money.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Viatris Inc. The Motley Fool has a disclosure policy.
SPONSORED:10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Top Betting Websites
*Stock Advisor returns as of November 20, 2020